Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOYCE ANN O'SHAUGHNESSY

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1790727709
CMS profile
307682
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$132,489.71

131 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOYCE ANN O'SHAUGHNESSY

NPI 1790727709 · CMS profile ID 307682

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790727709?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOYCE ANN O'SHAUGHNESSY, NPI 1790727709, CMS profile ID 307682. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790727709?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOYCE ANN O'SHAUGHNESSY, NPI 1790727709, CMS profile ID 307682. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790727709?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOYCE ANN O'SHAUGHNESSY, NPI 1790727709, CMS profile ID 307682, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–131 of 131 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1790727709?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

131 matching records · $132,489.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 131 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–131 of 131.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $155.5305/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238005932 CMS
Lilly USA, LLC $2,625.0004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186682711 CMS
Eli Lilly and Company $347.0004/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186662501 CMS
Eli Lilly and Company $347.0004/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186671509 CMS
Eli Lilly and Company $16.0004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186671513 CMS
Eli Lilly and Company $9.0004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186682695 CMS
Eli Lilly and Company $59.0004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186682697 CMS
Eli Lilly and Company $151.4804/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186732317 CMS
Eli Lilly and Company $278.0004/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186732319 CMS
Eli Lilly and Company $54.0004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186732321 CMS
Eli Lilly and Company $257.0004/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186744245 CMS
Novartis Pharmaceuticals Corporation $83.3304/24/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200598301 CMS
PFIZER INC. $3,748.0004/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1231516456 CMS
PFIZER INC. $750.0004/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1231540527 CMS
AstraZeneca Pharmaceuticals LP $4,000.0004/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206415669 CMS
Merck Sharp & Dohme LLC $640.0004/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238038532 CMS
AstraZeneca Pharmaceuticals LP $112.6303/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206793631 CMS
Lilly USA, LLC $3,937.5003/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186710505 CMS
Eli Lilly and Company $1,312.5003/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186662499 CMS
PFIZER INC. $73.8803/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231580930 CMS
Novartis Pharmaceuticals Corporation $83.3303/26/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200598297 CMS
Davol Inc. $585.0003/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1232209200 CMS
JAZZ PHARMACEUTICALS INC. $824.0003/05/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234300687 CMS
Genentech USA, Inc. $14.9303/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211528274 CMS
Stemline Therapeutics Inc. $38.8102/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244096075 CMS
Novartis Pharmaceuticals Corporation $83.3302/21/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200598295 CMS
Merck Sharp & Dohme LLC $2,240.0002/12/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238038214 CMS
Novartis Pharma AG $2,800.0002/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1247622809 CMS
Roche Products Limited $660.0001/29/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211528286 CMS
Novartis Pharmaceuticals Corporation $83.3301/23/2025 Long term medical supply or device loan No dispute reported Delay: No
Change: NEW
06/30/2026 1200598293 CMS
Roche Products Limited $990.0001/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211528284 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $229,965.22 168
PY2020 $143,165.92 83
PY2021 $219,820.94 100
PY2022 $179,312.78 107
PY2023 $321,923.38 167
PY2024 $117,051.40 101
PY2025 $132,489.71 131

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,692.10 1
PY2025 Principal investigator $2,197,057.85 290
PY2024 Recipient $16,309.73 6
PY2024 Principal investigator $2,131,024.81 441
PY2023 Recipient $12,701.28 3
PY2023 Principal investigator $1,471,216.58 184
PY2022 Recipient $6,226.33 7
PY2022 Principal investigator $2,253,653.42 192
PY2021 Recipient $18,330.18 12
PY2021 Principal investigator $4,264,639.31 288
PY2020 Recipient $16,390.95 17
PY2020 Principal investigator $4,218,641.50 1,696
PY2019 Recipient $8,324.67 3
PY2019 Principal investigator $2,912,468.34 905

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

291 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $753.77 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744792
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $341.35 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744794
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,024.92 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744796
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,270.62 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744798
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,431.55 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744800
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,270.62 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744802
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $390.65 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744804
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744806
Principal investigator 1 Merck Sharp & Dohme LLC $67,900.40 12/31/2025 Non-covered Recipient Entity
Texas Oncology - DFW
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received No dispute reported 06/30/2026 1232924428
Principal investigator 1 Merck Sharp & Dohme LLC $4,553.56 12/31/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 1232926043
Principal investigator 1 Merck Sharp & Dohme LLC $2,023.80 12/31/2025 Non-covered Recipient Entity
Texas Oncology- Plano East
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC No dispute reported 06/30/2026 1232926267
Principal investigator 1 Merck Sharp & Dohme LLC $5,954.96 12/31/2025 Non-covered Recipient Entity
Texas Oncology-Baylor Charles A. Sammons Cancer Center
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re No dispute reported 06/30/2026 1232926493
Principal investigator 1 Merck Sharp & Dohme LLC $5,954.96 12/31/2025 Non-covered Recipient Entity
Texas Oncology- Plano East
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re No dispute reported 06/30/2026 1232926495
Principal investigator 1 Merck Sharp & Dohme LLC $3,402.83 12/31/2025 Non-covered Recipient Entity
Texas Oncology-Dallas Presbyterian Hospital
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re No dispute reported 06/30/2026 1232927169
Principal investigator 1 Genentech, Inc. $1,363.00 12/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681868
Principal investigator 1 Genentech, Inc. $1,363.00 12/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681878
Principal investigator 1 Genentech, Inc. $165.00 12/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681880
Principal investigator 1 Genentech, Inc. $1,363.00 12/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681882
Principal investigator 1 Genentech, Inc. $247.00 12/19/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677541
Principal investigator 1 Genentech, Inc. $23,805.00 12/19/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681860
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742964
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 12/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742966
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,246.73 12/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742968
Principal investigator 1 Genentech, Inc. $165.00 12/04/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681864
Principal investigator 1 Genentech, Inc. $1,363.00 12/04/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681870
Principal investigator 1 Genentech, Inc. $1,363.00 12/04/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681884
Principal investigator 1 Genentech, Inc. $1,363.00 12/04/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681888
Principal investigator 1 Genentech, Inc. $1,363.00 12/04/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681892
Principal investigator 1 Genentech, Inc. $1,500.00 12/03/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211676211
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,205.16 11/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744780
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,936.12 11/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744782
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,053.00 11/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744784
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $137.15 11/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744786
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $390.65 11/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744788
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744790
Principal investigator 1 Genentech, Inc. $1,350.00 11/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681858
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 11/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742493
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 11/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742495
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,486.45 11/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742497
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742962
Principal investigator 1 Genentech, Inc. $10,000.00 11/14/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681848
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,111.76 11/11/2025 Non-covered Recipient Entity
BAYLOR HEALTH CARE SYSTEM / SAMMONS CANCER CENTER
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190313309
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,995.65 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742958
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742960
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,400.00 11/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742489
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $17,000.00 11/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742491
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10.00 10/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744774
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $975.00 10/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744776
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744778
Principal investigator 1 Exelixis Inc. $195.00 10/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379720
Principal investigator 1 Exelixis Inc. $3,380.00 10/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379722
Principal investigator 1 Exelixis Inc. $300.00 10/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379724
Principal investigator 1 Exelixis Inc. $1,267.50 10/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379726
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,551.50 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742952
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742954
Principal investigator 1 Genentech, Inc. $1,500.00 10/23/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677507
Principal investigator 1 Genentech, Inc. $247.00 10/22/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677521
Principal investigator 1 Genentech, Inc. $247.00 10/22/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677525
Principal investigator 1 PFIZER INC. $1,200.00 10/15/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228723082
Principal investigator 1 PFIZER INC. $650.00 10/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A PHASE 1 OPENLABEL DOSEESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SGNLIV1A IN PATIENTS WITH METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228726518
Principal investigator 1 Genentech, Inc. $293.00 10/09/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681826
Principal investigator 1 Genentech, Inc. $1,363.00 10/09/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681832
Principal investigator 1 Genentech, Inc. $1,363.00 10/09/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681836
Principal investigator 1 Genentech, Inc. $1,363.00 10/09/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681840
Principal investigator 1 Genentech, Inc. $165.00 10/09/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681842
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12,723.48 10/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742487
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742946
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,470.50 10/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742948
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $16,324.20 10/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742950
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,984.28 10/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742956
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744682
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,495.00 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744684
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $5,000.00 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744686
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,495.00 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744688
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,495.00 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744690
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $57.04 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744692
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $197.44 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744694
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,184.63 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744696
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $100.91 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744698
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,687.43 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744700
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,687.43 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744702
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,687.43 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744704
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $118.46 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744706
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,275.01 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744708
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $644.08 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744710
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,290.80 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744712
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $469.03 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744714
Principal investigator 1 PFIZER INC. $3,185.50 09/24/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228760234
Principal investigator 1 Genentech, Inc. $293.00 09/18/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681720
Principal investigator 1 Genentech, Inc. $1,417.73 09/18/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681752
Principal investigator 1 Genentech, Inc. $165.00 09/18/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681768
Principal investigator 1 Genentech, Inc. $1,417.73 09/18/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681822
Principal investigator 1 Exelixis Inc. $50.00 09/17/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379700
Principal investigator 1 Exelixis Inc. $12,869.03 09/17/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379706
Principal investigator 1 Genentech, Inc. $247.00 09/17/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677467
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744716
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,227.10 08/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744718
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $644.08 08/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744720
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,492.63 08/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744722
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,605.83 08/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744724
Principal investigator 1 Merck Sharp & Dohme LLC $117,954.40 08/31/2025 Non-covered Recipient Entity
US Oncology Research, Inc.
STUDY NAME#Pilot clinical trial of treatment with bortezomib to inhibit homologous recombination HR followed by pembrolizumab and cisplatin in patients with chemotherapy-pretreated metastatic triple negative breast cancer No dispute reported 06/30/2026 1232935517
Principal investigator 1 Genentech, Inc. $165.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681710
Principal investigator 1 Genentech, Inc. $265.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681714
Principal investigator 1 Genentech, Inc. $45.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681738
Principal investigator 1 Genentech, Inc. $1,417.73 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681740
Principal investigator 1 Genentech, Inc. $9,522.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681744
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681754
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681774
Principal investigator 1 Genentech, Inc. $165.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681780
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681782
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681792
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681796
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681798
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681808
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681810
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681812
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681814
Principal investigator 1 Genentech, Inc. $1,363.00 08/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681816
Principal investigator 1 Genentech, Inc. $2,098.00 08/25/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677477
Principal investigator 1 Genentech, Inc. $10,000.00 08/21/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681718
Principal investigator 1 Genentech, Inc. $20.00 08/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677487
Principal investigator 1 Genentech, Inc. $12,670.00 08/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677495
Principal investigator 1 Genentech, Inc. $1,350.00 08/07/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681746
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742481
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742483
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742485
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744726
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,184.63 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744728
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $32.47 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744730
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $74.59 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744732
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $57.04 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744734
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,472.45 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744736
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,687.43 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744738
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,687.43 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744740
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,687.43 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744742
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $302.74 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744744
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $197.44 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744746
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,605.83 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744748
Principal investigator 1 Exelixis Inc. $3,500.00 07/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379698
Principal investigator 1 Exelixis Inc. $7,500.00 07/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379702
Principal investigator 1 Exelixis Inc. $3,629.68 07/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379704
Principal investigator 1 Exelixis Inc. $1,750.00 07/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379708
Principal investigator 1 Exelixis Inc. $1,072.50 07/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379710
Principal investigator 1 Exelixis Inc. $24,030.50 07/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379712
Principal investigator 1 Exelixis Inc. $480.00 07/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379714
Principal investigator 1 Exelixis Inc. $50.00 07/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379716
Principal investigator 1 Exelixis Inc. $500.00 07/29/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379718
Principal investigator 1 PFIZER INC. $7,778.90 07/25/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228773821
Principal investigator 1 Genentech, Inc. $1,500.00 07/23/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677391
Principal investigator 1 AstraZeneca Pharmaceuticals LP $45,974.51 07/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185544813
Principal investigator 1 AstraZeneca Pharmaceuticals LP $95,712.32 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185544809
Principal investigator 1 PFIZER INC. $720.00 07/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228746036
Principal investigator 1 PFIZER INC. $720.00 07/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228746226
Principal investigator 1 PFIZER INC. $650.00 07/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A PHASE 1 OPENLABEL DOSEESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SGNLIV1A IN PATIENTS WITH METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228747974
Principal investigator 1 AstraZeneca UK Limited $5,250.00 07/09/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291) No dispute reported 06/30/2026 1185544821
Principal investigator 1 Janssen Research & Development, LLC $4,516.00 07/09/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287679
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744750
Principal investigator 1 PFIZER INC. $2,021.76 06/26/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228776135
Principal investigator 1 Genentech, Inc. $165.00 06/25/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681558
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,457.40 06/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185544819
Principal investigator 1 Genentech, Inc. $3,174.00 06/11/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681484
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,470.50 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742477
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,168.20 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742479
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744752
Principal investigator 1 Genentech, Inc. $10,193.00 05/28/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677118
Principal investigator 1 Genentech, Inc. $1,363.00 05/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681486
Principal investigator 1 Genentech, Inc. $165.00 05/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681502
Principal investigator 1 Genentech, Inc. $293.00 05/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681540
Principal investigator 1 Genentech, Inc. $1,363.00 05/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681610
Principal investigator 1 Genentech, Inc. $1,363.00 05/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681636
Principal investigator 1 Genentech, Inc. $1,363.00 05/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681662
Principal investigator 1 Genentech, Inc. $1,363.00 05/26/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681666
Principal investigator 1 Genentech, Inc. $1,350.00 05/19/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681596
Principal investigator 1 PFIZER INC. $311.50 05/15/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228773419
Recipient Novartis Pharmaceuticals Corporation $2,692.10 05/13/2025 Covered Recipient Physician China IITvsUS Flatiron AB No dispute reported 06/30/2026 1190292471
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $41,300.00 05/09/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and in combination with pembrolizumab in subjects with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced and unresectable or metas No dispute reported 06/30/2026 1235993865
Principal investigator 1 PFIZER INC. $1,622.51 05/08/2025 Non-covered Recipient Entity
Baylor Sammons Cancer Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228760157
Principal investigator 1 PFIZER INC. $2,333.26 05/06/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228783560
Principal investigator 1 Genentech, Inc. $247.00 05/05/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677321
Principal investigator 1 Genentech, Inc. $1,500.00 05/05/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677329
Principal investigator 1 Genentech, Inc. $6,348.00 05/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681510
Principal investigator 1 Genentech, Inc. $290.00 05/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681594
Principal investigator 1 AstraZeneca Pharmaceuticals LP $98,249.96 04/30/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185544805
Principal investigator 1 AstraZeneca Pharmaceuticals LP $40,834.24 04/30/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY, PA
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185544807
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744754
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,472.45 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744756
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $74.59 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744758
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,687.43 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744760
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,687.43 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744762
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,687.43 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744764
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,605.83 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744766
Principal investigator 1 Genentech, Inc. $1,500.00 04/25/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211676165
Principal investigator 1 Janssen Research & Development, LLC $2,258.00 04/16/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287670
Principal investigator 1 Janssen Research & Development, LLC $12,611.00 04/16/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287740
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,882.35 04/16/2025 Non-covered Recipient Entity
BAYLOR HEALTH CARE SYSTEM / SAMMONS CANCER CENTER
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190313311
Principal investigator 1 Genentech, Inc. $1,363.00 04/15/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681564
Principal investigator 1 Genentech, Inc. $165.00 04/15/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681580
Principal investigator 1 Genentech, Inc. $293.00 04/15/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681584
Principal investigator 1 Genentech, Inc. $1,363.00 04/15/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681620
Principal investigator 1 Genentech, Inc. $1,363.00 04/15/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681626
Principal investigator 1 PFIZER INC. $650.00 04/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A PHASE 1 OPENLABEL DOSEESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SGNLIV1A IN PATIENTS WITH METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228746040
Principal investigator 1 Janssen Research & Development, LLC $176.00 04/11/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287655
Principal investigator 1 Janssen Research & Development, LLC $94.00 04/11/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287714
Principal investigator 1 Janssen Research & Development, LLC $94.00 04/11/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287775
Principal investigator 1 Exelixis Inc. $1,000.00 04/10/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379684
Principal investigator 1 Exelixis Inc. $2,600.00 04/10/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379686
Principal investigator 1 Exelixis Inc. $2,600.00 04/10/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379688
Principal investigator 1 Exelixis Inc. $2,600.00 04/10/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379690
Principal investigator 1 Exelixis Inc. $2,600.00 04/10/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379692
Principal investigator 1 Exelixis Inc. $4,225.00 04/10/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379694
Principal investigator 1 Exelixis Inc. $474.50 04/10/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379696
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 04/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742467
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,470.50 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742465
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,100.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742469
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 03/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744768
Principal investigator 1 Genentech, Inc. $45.00 03/24/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681448
Principal investigator 1 Genentech, Inc. $12,696.00 03/24/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681450
Principal investigator 1 Genentech, Inc. $11,728.00 03/24/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681464
Principal investigator 1 Genentech, Inc. $293.00 03/24/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681466
Principal investigator 1 Genentech, Inc. $1,363.00 03/24/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681478
Principal investigator 1 Genentech, Inc. $1,363.00 03/24/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681678
Principal investigator 1 Genentech, Inc. $293.00 03/24/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681694
Principal investigator 1 Genentech, Inc. $1,363.00 03/24/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681700
Principal investigator 1 PFIZER INC. $1,622.51 03/24/2025 Non-covered Recipient Entity
Baylor Sammons Cancer Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228770304
Principal investigator 1 PFIZER INC. $2,021.76 03/22/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228779868
Principal investigator 1 Genentech, Inc. $247.00 03/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677197
Principal investigator 1 Genentech, Inc. $20.00 03/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677276
Principal investigator 1 Genentech, Inc. $247.00 03/20/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677309
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,705.50 03/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185544799
Principal investigator 1 Novartis Pharmaceuticals Corporation $226,335.00 03/06/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY
Patient Journey, Treatment Patterns, and Clinical Outcomes of Women Diagnosed With HR+/HER2 Early-Stage Breast Cancer No dispute reported 06/30/2026 1190301837
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742471
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742473
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $10,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742475
Principal investigator 1 PFIZER INC. $4,626.70 03/04/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228783578
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 02/28/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744770
Principal investigator 1 Janssen Research & Development, LLC $2,587.00 02/26/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287579
Principal investigator 1 Genentech, Inc. $1,875.00 02/19/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677146
Principal investigator 1 PFIZER INC. $3,245.02 02/19/2025 Non-covered Recipient Entity
Baylor Sammons Cancer Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228770502
Principal investigator 1 PFIZER INC. $295.00 02/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228750417
Principal investigator 1 Exelixis Inc. $2,632.50 02/14/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379680
Principal investigator 1 PFIZER INC. $4,043.52 02/14/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228752871
Principal investigator 1 PFIZER INC. $2,271.36 02/13/2025 Non-covered Recipient Entity
Texas Oncology PA
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228749395
Principal investigator 1 Janssen Research & Development, LLC $1,411.00 02/12/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287571
Principal investigator 1 Janssen Research & Development, LLC $2,587.00 02/12/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287595
Principal investigator 1 Janssen Research & Development, LLC $1,411.00 02/12/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287644
Principal investigator 1 Janssen Research & Development, LLC $1,125.00 02/12/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287697
Principal investigator 1 Exelixis Inc. $4,511.00 02/06/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379664
Principal investigator 1 Exelixis Inc. $1,852.50 02/06/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379666
Principal investigator 1 Exelixis Inc. $1,200.00 02/06/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379668
Principal investigator 1 Exelixis Inc. $3,510.00 02/06/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379670
Principal investigator 1 Exelixis Inc. $2,600.00 02/06/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379672
Principal investigator 1 Exelixis Inc. $832.00 02/06/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379674
Principal investigator 1 Exelixis Inc. $4,511.00 02/06/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379676
Principal investigator 1 Exelixis Inc. $1,072.50 02/06/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379678
Principal investigator 1 Exelixis Inc. $125.00 02/06/2025 Non-covered Recipient Entity
Baylor Scott & White Research Institute
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379682
Principal investigator 1 Genentech, Inc. $1,500.00 02/05/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211676152
Principal investigator 1 Genentech, Inc. $165.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681494
Principal investigator 1 Genentech, Inc. $64.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681506
Principal investigator 1 Genentech, Inc. $293.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681518
Principal investigator 1 Genentech, Inc. $106.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681528
Principal investigator 1 Genentech, Inc. $1,363.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681532
Principal investigator 1 Genentech, Inc. $1,350.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681560
Principal investigator 1 Genentech, Inc. $114.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681562
Principal investigator 1 Genentech, Inc. $1,363.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681616
Principal investigator 1 Genentech, Inc. $1,363.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681664
Principal investigator 1 PFIZER INC. $325.00 02/03/2025 Non-covered Recipient Entity
Baylor Sammons Cancer Center
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228768885
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 01/31/2025 Non-covered Recipient Entity
Texas Oncology
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233744772
Principal investigator 1 Janssen Research & Development, LLC $1,176.00 01/31/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287611
Principal investigator 1 PFIZER INC. $694.00 01/27/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228800936
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,844.81 01/24/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185544815
Principal investigator 1 Merck Sharp & Dohme LLC $48,320.94 01/22/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE BAYLOR SCOTT AND WHITE RESEARCH INSTITUTE
Assessment of translation biomarkers in patients with chemotherapy-pretreated metastatic triple negative breast cancer who have been treated with bortezomib to inhibit homologous recombination HR followed by pembrolizumab and cisplatin No dispute reported 06/30/2026 1232937854
Principal investigator 1 Eli Lilly and Company $52,623.00 01/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187892834
Principal investigator 1 Genentech, Inc. $10,672.00 01/21/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211677167
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,685.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185544795
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,819.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185544797
Principal investigator 1 AstraZeneca Pharmaceuticals LP $328,063.00 01/15/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185544801
Principal investigator 1 AstraZeneca Pharmaceuticals LP $858.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 1185544803
Principal investigator 1 AstraZeneca Pharmaceuticals LP $797.78 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) No dispute reported 06/30/2026 1185544811
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,385.10 01/15/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) No dispute reported 06/30/2026 1185544823
Principal investigator 1 Eli Lilly and Company $17,865.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187890542
Principal investigator 1 Eli Lilly and Company $37,865.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 1187890870
Principal investigator 1 Eli Lilly and Company $0.33 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 1187893334
Principal investigator 1 PFIZER INC. $650.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A PHASE 1 OPENLABEL DOSEESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SGNLIV1A IN PATIENTS WITH METASTATIC BREAST CANCER No dispute reported 06/30/2026 1228745774
Principal investigator 1 PFIZER INC. $956.00 01/15/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS DRIVEN BY HER2 ALTERATIONS No dispute reported 06/30/2026 1228746032
Principal investigator 1 Janssen Research & Development, LLC $1,411.00 01/14/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287562
Principal investigator 1 Janssen Research & Development, LLC $1,176.00 01/14/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287618
Principal investigator 1 Eli Lilly and Company $21,290.70 01/09/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A STUDY OF LOXO-783 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ANTICANCER THERAPIES FOR PATIENTS WITH ADVANCED BREAST CANCER AND OTHER SOLID TUMORS WITH A PIK3CA H1047R MUTATION No dispute reported 06/30/2026 1187890538
Principal investigator 1 Eli Lilly and Company $25,227.00 01/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY No dispute reported 06/30/2026 1187890594
Principal investigator 1 Eli Lilly and Company $0.04 01/06/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187891756
Principal investigator 1 AstraZeneca Pharmaceuticals LP $77,337.68 01/03/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer No dispute reported 06/30/2026 1185544817
Principal investigator 1 Eli Lilly and Company $83,190.30 01/03/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
Not supplied No dispute reported 06/30/2026 1187892798